Cardiogen vs Omega-3 (EPA/DHA)
A side-by-side research comparison of Cardiogen and Omega-3 (EPA/DHA) across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Cardiogen | Omega-3 (EPA/DHA) |
|---|---|---|
| Full name | Cardiogen (Ala-Glu-Asp-Arg Cardiac Bioregulator) | Omega-3 Fatty Acids (EPA + DHA) |
| Category | Cardiovascular | Cardiovascular |
| Status | Research compound (peptide bioregulator) | Dietary supplement / FDA-approved (Rx fish oil) |
| Mechanism | As a signal peptide (Ala-Glu-Asp-Arg), it is proposed to regulate gene expression in myocardial tissue, supporting cardiomyocyte function, myocardial protein synthesis, and normal cardiac tissue maintenance. | EPA/DHA incorporate into cell membranes, displacing arachidonic acid and reducing pro-inflammatory eicosanoid production. Generate resolvins and protectins for active inflammation resolution. Activate PPARγ and inhibit NF-κB. |
| Molecular weight | ~460 Da | EPA: 302.45 Da, DHA: 328.49 Da |
| Half-life | Short (peptide) | ~48-72 hours (membrane incorporation) |
| Bioavailability | Oral (encapsulated) or subcutaneous | Triglyceride form: ~70%; ethyl ester: ~30-40%; phospholipid (krill): ~85% |
| Typical dose | ~1-2 capsules/day or short injectable courses | 2-4g combined EPA+DHA |
| Frequency | Once daily | Daily with meals |
| Route | Oral capsule or subcutaneous | Oral (softgel, liquid) |
Cardiogen reported benefits
- Cardiac/myocardial tissue support
- Cardiovascular resilience (proposed)
- Myocardial protein synthesis support
- Short course-based protocol
Omega-3 (EPA/DHA) reported benefits
- Triglyceride reduction (25-45%)
- Anti-inflammatory (SPM production)
- Cardiac rhythm stabilization
- Brain and cognitive support
- Joint inflammation reduction
- Membrane fluidity optimization
Related comparisons
Research and educational reference only. Not medical advice.